Actos Bladder Cancer Lawsuit Verdict Reinstated
A California appeals court has reinstated a $6.5 million verdict against Takeda Pharmaceutical Company that was nullified by the trial judge over two years ago in the first Actos bladder cancer lawsuit to go to trial. A three-justice panel in California’s Second District Court of Appeal ruled today that Los Angeles County Superior Court Judge Kenneth Freeman erred in striking the testimony of key plaintiffs’ expert Dr. Norm Smith and overturning the jury’s verdict.
Takeda Pharmaceuticals has filed its second required report to U.S. District Court Judge Rebecca Doherty in compliance with Judge Doherty’s order that the Japanese drug maker and its related corporations in Europe and the United States recover missing emails and documents belonging to 46 key Takeda employees. In the report Takeda states that it has recovered 61,000 emails and attachments that were either sent or received by one or more of the 46 employees, referred to as the “document custodians.” The emails were recovered from a Postini (a cloud computing email and Web security service) email archive.
Takeda and Eli Lilly Sued Over Actos Bladder Cancer Claims
The law firm of Baum, Hedlund, Aristei & Goldman has filed lawsuits on behalf of several people who claim their bladder cancer was caused by taking a diabetes drug called Actos (pioglitazine). The lawsuits were filed in federal court in Louisiana and California state court against Takeda Pharmaceutical Company USA and Eli Lilly, the companies that manufactured Actos and brought the drug to market in the US.
Judge Denies Motion to Overturn $9 Billion Actos Jury Award
A federal judge has denied a motion by Takeda Pharmaceuticals and Eli Lilly and Company to overturn the verdict of a jury that recently ordered the two drug makers to pay $1.5 million in compensatory damages and $9 billion in punitive damages to the plaintiff after finding that Takeda hid evidence linking its diabetes drug, Actos, to an increased risk of bladder cancer. The plaintiff in the case, Terrance Allen, blamed Actos for his bladder cancer.
Insurance Company Files Actos Bladder Cancer Lawsuit
Blue Cross and Blue Shield of Massachusetts (BCBSMA) has filed a lawsuit, on behalf of its insured members, against Takeda Pharmaceuticals, maker of the diabetes drug, Actos. The suit charges the Japanese company with hiding evidence that Actos causes bladder cancer and also names Takeda’s U.S. marketing partner, Eli Lilly and Company.
A federal judge in Louisiana has ruled that Takeda Pharmaceuticals intentionally destroyed evidence relevant to multidistrict litigation involving Takeda’s diabetes drug Actos. The ruling affects over 6,000 lawsuits that have been consolidated before U.S. District Judge Rebecca Doherty, who issued today’s ruling. Plaintiffs in those cases have charged Takeda with concealing evidence and failing to warn patients and health care providers that Actos significantly increases the risk of bladder cancer.
A District Court judge has issued sanctions against lawyers for Takeda Pharmaceuticals in a trial currently underway in Las Vegas. In an order filed yesterday, the judge ruled that attorneys for Takeda violated pretrial evidentiary rulings nine times and “repeatedly engaged in disruptive and disrespectful behavior towards the court.” Plaintiffs in the case, Delores Cipriano, 81, of Henderson, NV, and Bertha Triana, 80, of Las Vegas, are both suffering from bladder cancer, which they claim was caused by Takeda’s diabetes drug, Actos. They are seeking a multibillion-dollar verdict against the Japanese drug maker.
Takeda, Lilly Jury Awards $9 Billion Over Actos Risks
Trial Starts for Two Nevada Women who Developed Bladder Cancer after taking Actos